Four years overall experience with a new low estrogen -- low progestogen oral contraceptive.
The reliability and the overall clinical acceptance of a new combined oral contraceptive, containing 30 mcg of ethinyl estradiol and 0.15 mg of D-norgestrel, was studied in 102 patients over 1,731 cycles. The results have been accumulated over a period of four years, some of the subjects still using the presented formulation. No pregnancy occurred during the observation period. Out of the totally observed cycles, 94.3 per cent had a duration of 28 +/- 2 days. In only 1.7 per cent of the cycles did withdrawal bleeding fail to appear. Spotting and breakthrough bleeding occurred 3.6 and 3.8 per cent of the cycles respectively. The incidence of side-effects reported by the users and commonly associated with oral contraceptive use was relatively low.
D000328:Adult; D001835:Body Weight; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000139:chemically induced; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D004997:Ethinyl Estradiol